Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib
Keywords: 
Hemangioendothelioma
Liver
Sorafenib
Issue Date: 
2012
Publisher: 
PAGEpress
ISSN: 
2036-3605
Citation: 
Sangro B, Iñarrairaegui M, Fernández-Ros N. Malignant epithelioid hemangioendothelioma of the liver successfully treated with Sorafenib. Rare Tumors. 2012 Apr 12;4(2):e34.
Abstract
Hepatic epithelioid hemangioendothelioma (HEH) is a rare disease of unknown etiology for which a standard systemic treatment has not been established. The common expression of vascular endothelial growth factor (VEGF) and its receptor in HEH provide a rationale for the reported use of antiangiogenic drugs, including bevacizumab, lenalidomide and thalidomide. We report a case of a young male patient with HEH who was treated with sorafenib for almost 2 years. Sorafenib was used instead of other VEGF inhibitors due to its convenient oral route, its dual antiangiogenic and antiproliferative activity, and its favorable safety profile. Sorafenib therapy resulted in durable stabilization with progressive calcification of liver tumors and minor but stable response of lung lesions.

Files in This Item:
File: 
Rare Tum rt-2012-2-e34.pdf
Description: 
Size: 
309,94 kB
Format: 
Adobe PDF


Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.